Prof Maarten J Postma

Prof Maarten J Postma (29/01/1960) holds the chair Global Health Economics at the University Medical Center Groningen (UMCG) and the faculty of Economics & Business, both at the University of Groningen and is director of UMCG’s research institute SHARE. Also, he is Prof in Pharmacoeconomics at the Groningen Research Institute of Pharmacy and holds an honorary chair at the Airlangga University (Surabaya, Indonesia). He did his MSc in econometrics and his PhD in health economics. He specifically leads a team of 50 staff, PhD and post-doc researchers in health- and pharmacoeconomics, contributing to many international research networks and scientific communications. Research areas comprise cost-effectiveness methods, for example, in vaccinology, transfusion science, “expensive drugs” and personalized medicine. He serves (served) on various committees advising the Dutch government on reimbursement of drugs and vaccines (CVZ/ZiNL and Health Council). Also, he is advisor to various health-economics consultancy companies and pharmaceutical companies worldwide, Ministries of Health in neighbouring countries, member of editorial boards of scientific journals, on advisory boards for pharmaceutical companies and expert consultant for WHO. He is a member of UK’s Joint Committee of Vaccination & Immunization and advisor to the All Wales Medicines Strategy Group (Grwp Strategaeth Meddyginiaethau Gymru Gyfam). He is specialized in the role of pharmacoeconomics/health economics in the reimbursement process. He has over 375 MEDLINE-publications, an H-factor of 44 and extensive teaching/lecturing experience (Groningen, Heidelberg, Sofia, Utrecht, Bielefeld, Ankara, Indonesia, JoBurg and Vietnam). So far, he attracted 10 EU-projects (2 recent projects in infectious diseases’ vaccinology and diagnostics), 7 WHO-projects, various national projects from the National Institute of Public Health and the MoH and multiple projects from pharma, aggregating to over 10 million EUR in the last decade. He is involved in 5 spin-off consultancy companies from the University.